retatrutide dose clinical trials Side Effects Research retatrutide clinical trial dosing frequency

The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS

While GLP-1 therapies are not FDA indicated for all of these conditions, growing evidence suggests they can improve outcomes across each 3

~14% with semaglutide over 72 weeks

Mechanisms in Bariatric Surgery: Gut Hormones, Diabetes Resolution, and Weight Loss

The STEP-HFpEF trial was a randomized, double-blind, placebo-controlled trial that analysed the effects of weekly subcutaneous semaglutide in patients with obesity-related HFpEF

drug prices exceed global norms, treating affordability as a public health imperative